Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia
(AML) that is used for prognostic, predictive, monitoring, and efficacy-response …

PURPOSE Patients with acute myeloid leukemia (AML) in remission remain at risk for
relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable …

In recent years, major advances in the understanding of acute myeloid leukemia (AML)
pathogenesis, together with technological progress, have led us into a new era in the …

The detection of measurable residual disease (MRD) has become a key investigation that
plays a role in the prognostication and management of several hematologic malignancies …

We accrued 201 patients of adult AML treated with conventional therapy, in morphological
remission, and evaluated MRD using sensitive error-corrected next generation sequencing …

Ultra-deep next-generation sequencing has emerged in recent years as an important
diagnostic tool for the detection and follow-up of tumor burden in most of the known …

Risk-stratification of acute myeloid leukemia (AML) based on recurrent somatic
abnormalities has evolved substantially in recent years, as illustrated by the current 2017 …

Multiple studies have demonstrated that patients with acute myeloid leukemia (AML) who
have measurable residual disease (MRD) detected during or after treatment have higher …

Acute myeloid leukaemia (AML) is a blood cancer characterized by acquired genetic
mutations. There is great interest in accurately establishing measurable residual disease …

MRD technologies increase our ability to measure response in acute myeloid leukemia
(AML) beyond the limitations of morphology. When applied in clinical trials, molecular and …